GlassScriptPhysician profile
Arielle Spitze
NPI 1760689277
$9,571.12
in general payments reported to CMS, 2019-2025
28 companies · $2,289 in 2025
The $2,289 reported for 2025 was more than what 89% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $927 · 2020: $400 · 2021: $631 · 2022: $1,355 · 2023: $1,203 · 2024: $2,765 · 2025: $2,289.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,855 · Travel and Lodging: $825 · Consulting Fee: $475 · Education: $102.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,855.43 |
| Travel and Lodging | $825.26 |
| Consulting Fee | $475.00 |
| Education | $102.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,789.54 | 2022-2025 | Xen Glaucoma Treatment System, Durysta, Lumigan |
| Alcon Vision LLC | $1,862.03 | 2019-2025 | Argos, Clareon, Clareon Panoptix Pro |
| Allergan, INC. | $842.96 | 2019-2022 | |
| Horizon Therapeutics Plc | $780.32 | 2022-2023 | Tepezza, Uplizna |
| Alexion Pharmaceuticals, INC. | $684.57 | 2019-2025 | Ultomiris, Soliris |
| Bausch & Lomb Americas INC. | $457.78 | 2022-2025 | Miebo, Vyzulta, Xiidra |
| Aerie Pharmaceuticals, INC. | $306.77 | 2019-2021 | |
| Amgen INC. | $238.39 | 2024-2025 | Tepezza, Uplizna |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $198.98 | 2019-2021 | |
| Mallinckrodt Hospital Products INC. | $181.21 | 2024 | Acthar |
| Sun Pharmaceutical Industries INC. | $155.97 | 2019-2025 | Cequa |
| Shire North American Group INC | $135.41 | 2019 | |
| Sight Sciences, INC. | $120.44 | 2019-2021 | |
| Harrow Eye, LLC | $109.62 | 2024-2025 | Vevye |
| Tarsus Pharmaceuticals, INC. | $106.27 | 2024-2025 | Xdemvy |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $97.63 | 2019 | |
| Oyster Point Pharma, INC. | $92.48 | 2022-2023 | Tyrvaya |
| Glaukos Corporation | $65.93 | 2024-2025 | Idosetr, Idose |
| Ucb, INC. | $62.16 | 2025 | Rystiggo |
| Novartis Pharmaceuticals Corporation | $55.15 | 2019-2022 | |
| Kala Pharmaceuticals, INC. | $48.84 | 2019-2021 | |
| Thea Pharma INC. | $41.17 | 2023-2025 | Iyuzeh |
| Biotissue Holdings INC. | $32.37 | 2020-2022 | |
| Rxsight INC | $27.77 | 2025 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Rxsight Contact Lens |
| New World Medical,INC. | $25.63 | 2023-2024 | Ahmed Glaucoma Valve, Clearpath, Kahook Dual Blade |
| Nova Eye, INC. | $22.21 | 2025 | |
| Omeros Corporation | $19.62 | 2019 | |
| Iridex Corporation | $9.90 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arielle Spitze listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.